Company · CIK 1980845
enGene Therapeutics Inc.
| CIK | 1980845 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2836 — Biological Products, (No Diagnostic Substances) |
| Incorporated in | Z4 |
| Listed | ENGN (Nasdaq), ENGNW (Nasdaq) |
| First annual or quarterly report | 2024-01-29 |
Offerings
4 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-293597 | 2026-02-19 | 2026-03-09 | 3 | |
| 333-283201 | 2024-11-13 | 2025-11-14 | 5 | |
| 333-283202 | 2024-11-13 | 2024-11-21 | 2 | |
| 333-275700 | 2023-11-22 | 2024-03-05 | 4 |
Filings
16| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2026-03-09 | 424B5Shelf takedown | 333-293597 | 0001193125-26-097563 |
| 2026-03-02 | EFFECTDeclared effective | 333-293597 | 9999999995-26-000700 |
| 2026-02-19 | S-3Shelf registered | 333-293597 | 0001193125-26-059479 |
| 2025-11-14 | 424B5Shelf takedown | 333-283201 | 0001193125-25-281504 |
| 2025-11-12 | 424B5Shelf takedown | 333-283201 | 0001193125-25-277833 |
| 2024-12-20 | 424B5Shelf takedown | 333-283201 | 0000950170-24-138766 |
| 2024-11-21 | EFFECTDeclared effective | 333-283202 | 9999999995-24-003546 |
| 2024-11-21 | EFFECTDeclared effective | 333-283201 | 9999999995-24-003545 |
| 2024-11-13 | S-3Shelf registered | 333-283202 | 0000950170-24-126454 |
| 2024-11-13 | S-3Shelf registered | 333-283201 | 0000950170-24-126446 |
| 2024-03-05 | EFFECTDeclared effective | 333-275700 | 9999999995-24-000603 |
| 2024-02-27 | S-1/AAmendment | 333-275700 | 0001193125-24-046578 |
| 2023-12-15 | S-1/AAmendment | 333-275700 | 0001193125-23-296741 |
| 2023-11-22 | S-1Registration filed | 333-275700 | 0001193125-23-281677 |
| 2023-09-29 | EFFECTDeclared effective | 333-273851 | 9999999995-23-002876 |
| 2023-06-14 | DRSDraft made public | 377-06746 | 0000950123-23-005719 |